Abstract
Treatment options of patients with advanced head and neck cancer developed in the last years. Surgical approaches with or without radiotherapy used to be the standard therapy for a long time. Calls for organ preservation, poor overall survival and unsatisfactory quality of life made changes in this therapy regime necessary. Systemical approaches were evaluated, first concepts of platinum-based chemotherapy paired with 5-fluorouracil (PF) made up the basis of induction chemotherapy (ICT). Hypothesized advantage of this regime was improvement in local and distant tumor responsiveness with an acceptable toxicity profile. Further investigations proved the addition of docetaxel (TPF) superior to PF, which presents the gold standard of current induction chemotherapy regimes. Long-term results underlining well-known aspects of this regime as well as new approaches of induction chemotherapy were published at ASCO 2011, including the addition of bioimmunotherapy to radiotherapy, adding nanoparticle-bound albumin to chemotherapy and investigations in toxicity reduction. Further investigations are still made not only to increase survival outcomes and local control but also to improve quality of life by reducing acute and late toxicities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
(1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324(24):1685–1690
Paccagnella A et al (2010) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 21(7):1515–1522
Vermorken JB et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704
Posner MR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715
Vermorken JB et al (2011) Long-term results from EORTC24971/TAX323: comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts 29(15_suppl), p 5530
Sher DJ et al (2011) Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys, 2011
Paccagnella A et al (2011) Concomitant chemoradiation or RT/cetuximab versus induction TPF followed by chemoradiation or RT/cetuximab in locally advanced head and neck squamous cell carcinoma: a randomized phase III factorial study. ASCO Meeting Abstracts 29(15_suppl), p TPS196
Forastiere AA et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098
Caudell JJ et al (2011) Concurrent chemoradiotherapy with or without induction chemotherapy for locally advanced head and neck cancer. ASCO Meeting Abstracts 29(15_suppl):5553
Fayette J et al (2011) A comparison of neoadjuvant TP (nTP; docetaxel, T; cisplatin, P) versus nTPF in patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC). ASCO Meeting Abstracts 29(15_suppl):e16006
Adkins D et al (2011) Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). ASCO Meeting Abstracts 29(15_suppl), p 5560
Kuperman DI et al (2011) Safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in 30 patients (pts) with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC). ASCO Meeting Abstracts 29(15_suppl), p e16025
Mercke C et al (2011) Survival, tumor control, and toxicity with TPF before accelerated radiotherapy potentiated with cetuximab for stage III-IV unresectable head and neck cancer: A phase II study. ASCO Meeting Abstracts 29(15_suppl), p 5552
Lucas ZD et al (2011) Sequential treatment of locally advanced squamous cell carcinoma of the oropharynx (LASCCO) using docetaxel, cisplatin, and 5-fluorouracil (TPF) induction regimen: Retrospective results from a single institution. ASCO Meeting Abstracts 29(15_suppl):e16015
Atassi B et al (2011) Influence of induction chemotherapy on patients’ compliance to radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. ASCO Meeting Abstracts 29(15_suppl), p 5558
Agbahiwe HC et al (2011) Lymph node density and response to induction TPF in patients with HPV-related head and neck cancer. ASCO Meeting Abstracts 29(15_suppl), p 5576
Seiwert TY et al (2011) A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). ASCO Meeting Abstracts 29(15_suppl), p 5519
D’Angelillo RM et al (2011) Induction chemotherapy with cisplatin, 5-fluorouracil, and cetuximab followed by radiotherapy and cetuximad in head and neck cancers: Preliminary results of a modern integrated approach. ASCO Meeting Abstracts 29(15_suppl), p e16030
Lefebvre J et al (2011) Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study. ASCO Meeting Abstracts 29(15_suppl), p 5501
al-Sarraf M et al (1990) Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. J Clin Oncol 8(8):1342–1351
Hegde UP, Dowsett R, Spiro J (2011) Induction chemotherapy (ICT) containing docetaxel, platinum, and 5 fluorouracil (DPF) regimen in a sequential treatment of locally advanced nasopharyngeal cancer (LANPC): retrospective analysis from a single institution. ASCO Meeting Abstracts 29(15_suppl):e16037
Ho GF (2011) Induction and concurrent chemoradiotherapy with cetuximab for patients with locally advanced nasopharyngeal carcinoma. ASCO Meeting Abstracts 29(15_suppl):e16031
Yamouni M et al (2011) A phase II trial of induction chemotherapy with cisplatin, docetaxel, and capecitabine followed by concurrent cisplatin-radiotherapy in advanced nasopharyngeal carcinoma. ASCO Meeting Abstracts 29(15_suppl):5543
Conflict of interest
The authors have declared that no conflict of interest exists.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mumme, A.M., Laban, S. & Knecht, R. New aspects of induction chemotherapy for head and neck cancer: POSTASCO 2011. Eur Arch Otorhinolaryngol 269, 2303–2308 (2012). https://doi.org/10.1007/s00405-012-1999-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-012-1999-2